Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2B | Q02880 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711428 | 1.00 | TOP2B (0.43) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL542142 | 0.91 | TOP2B (0.44) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL542143 | 0.91 | TOP2B (0.44) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| Cadazolid SCHEMBL541618 | 0.91 | KDM4E (0.52) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| Cadazolid SCHEMBL29379581 | 0.91 | KDM4E (0.52) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| Cadazolid SCHEMBL541681 | 0.91 | KDM4E (0.52) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL712051 | 0.90 | TOP2B (0.41) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL712052 | 0.88 | KDM4E (0.39) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL541619 | 0.88 | KDM4E (0.42) | TOP2BKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL712050 | 0.87 | TOP2B (0.38) | TOP2BKDM4EALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| EP-2086968-B1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
| EP-2086968-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008056335-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | TOP2B 4619/4885KDM4E 1365/4885ALDH1A1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.